Coherus Oncology, Inc.

Healthcare

NASDAQ:CHRS · NASDAQ Global Market

Market Cap $170.15M Beta 0.96 P/E (TTM) -1.3

$1.48 +1.80%

+$0.03 today

52W Low $0.71High $2.62

Vol 1.26M · Avg 1.15M

EPS (TTM) -$1.11Biotechnology

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

+103.66%

Period High

$2.51

Period Low

$0.72

Latest

$1.48

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

SELLAS Life Sciences Group, Inc.

NASDAQ:SLS

$1.18B

C4 Therapeutics, Inc.

NASDAQ:CCCC

$335.80M

OmniAb, Inc.

NASDAQ:OABI

$259.07M

Codexis, Inc.

NASDAQ:CDXS

$226.79M

Protalix BioTherapeutics, Inc.

AMEX:PLX

$169.60M

Avalo Therapeutics, Inc.

NASDAQ:AVTX

$169.58M

Protara Therapeutics, Inc.

NASDAQ:TARA

$155.32M

Insight Molecular Diagnostics Inc.

NASDAQ:IMDX

$143.87M

Invivyd, Inc.

NASDAQ:IVVD

$128.31M

Sangamo Therapeutics, Inc.

NASDAQ:SGMO

$72.83M

What is the latest CHRS filing?

The latest filing shown is 8-K dated Jun 15, 2026.

How many recent filings does CHRS have?

Intrinsic Alpha currently shows 20 recent filings for CHRS.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.